Abstract ADAMTS9 is a member of the disintegrin and metalloproteinase with thrombospondin motifs (ADAM-TS) genes, with aggrecan-degrading activity. It has also been characterized to be reactive and highly activated ADAMTS by IL-1b in both chondrosarcoma cells and human chondrocytes (Demircan et al. Arthritis Rheum 52:1451-1460 , 2005 . In order to understand the regulation of ADAMTS9 gene expression a functional 3.0 kb human ADAMTS9 promoter has been cloned and characterized. A sequence analysis of the promoter revealed the presence of putative binding sites for Nuclear Factor of Activated T cells (NFAT), which is commonly found in the ADAMTS4 and ADAMTS5 promoters. NFATc1 was up-regulated in an activated form by IL-1b in human chondrocytes. The IL-1b inducible ADAMTS9 expression was inhibited by NFAT inhibitors, FK506 and 11Arg (11R)-VIVIT. Furthermore, direct binding of NFATc1 on distal and proximal promoters of ADAMTS9 was demonstrated by a chromatin immunoprecipitation assay. Promoter-reporter assays supported those results. These findings may provide a better understanding of the regulation of ADAMTS9 expression induced by inflammatory cytokines.
Introduction
Articular cartilage is an aneural, avascular, alymphatic connective tissue which covers the articulating ends of diarthrodial joints. It is characterized morphologically by a small number of chondrocytes which are responsible for the production, organization, and maintenance of an expansive extracellular matrix. The balance between the hydration of matrix proteoglycans and the resistance to expansion imposed by the collagen network ultimately provides the hydrodynamic load bearing properties of articular cartilage critical for joint articulation and the smooth transmission of mechanical compression across the joint [1] . Aggrecan is the major proteglycan of hyaline cartilage where it is present at a very high concentration in the form of aggregates, but it is also present in significant concentrations in the extracellular matrices of other tissues, including the meniscus, tendon, brain, and muscle [2] . Degradation of aggrecan and type II collagen by proteases is considered to be a critical early event of cartilage destruction in osteoarthritis (OA) and rheumatoid arthritis (RA). The inhibition of aggrecan degradation likely plays a protective role in the prevention of cartilage collagen breakdown [3] . The primary proteases responsible for aggrecan cleavage, aggrecanases, are members of the ADAMTS (A Disintegrin And Metalloprotease with TromboSpondin motifs) family of metalloproteases [4] . Certain members of the ADAMTS family (ADAMTS1, ADAMTS4, ADAMTS5, ADAMTS8, ADAMTS9, and ADAMTS15) are called 'aggrecanases' and they can proteolytically process aggrecan within the interglobular domain by separating its globular G1 and G2 of domains at a specific Glu 373 -Ala 374 bond [5] [6] [7] or at one or more sites within the more C-terminal glycosaminoglycan-bearing region [8] .
The nuclear factor of activated T cells (NFAT) proteins are a family of transcription factors related to Rel/NFjB family whose activation is controlled by calcineurin [9, 10] . Recently, an NFAT inhibitor peptide, VIVIT, was developed based on the conserved calcineurin docking site of the NFAT family [11] . Polyarginine peptides, protein transduction domains (PTD) also called cell penetrating peptides; facilitate the uptake of peptides and protein into cultured mammalian cells with high efficiency. The 11R-VIVIT peptide, consists of untadecaarginine as PTD fused with VIVIT, is designed to be efficiently transduced to interfere selectively with calcineurin-NFAT interaction without affecting calcineurin phosphatase activity, so it may be useful as a therapeutic agent that is less toxic than current drugs [12] .
Cytokines such as IL-1b have been shown to markedly upregulate ADAMTS9 expression in OUMS-27 chondrosarcoma cells and in human chondrocytes [13] . However, the pathways involved in the regulation of ADAMTS9 expression have not yet been elucidated in detail. NFAT is expressed in many cell types and contributes to diverse cellular functions [9, 14] . It was demonstrated that NFAT is one of the activator proteins for ADAMTS4 [15] and MMP-9, a type IV collagenase and plays an important role in the degradation of the extracellular matrix [16] . These findings and the presence of putative NFAT binding elements (NBE) in the ADAMTS9 promoter region prompted an investigation of whether NFAT is one of the activators for ADAMTS9 upon IL-1b stimulation. ADAMTS9 expression was inhibited by the NFAT inhibitors, 11R-VIVIT and FK506. Furthermore, the distal and proximal NBEs in the ADAMTS9 promoter were characterized. This study, demonstrated that both the distal and proximal NBEs contribute to the ADAMTS9 expression upon IL-1b stimulation in OUMS-27 chondrosarcoma cells and in human chondrocytes.
Materials and methods

Reagents
Recombinant human IL-1b was purchased from R&D Systems (Minneapolis, MN). The cytokines were stored at -80°C and then were immediately diluted in a culture medium prior to use. The following primary antibodies were purchased and used: mouse anti-NFATc1 antibody (7A6) (Santa Cruz Biotechnology, Santa Cruz, CA), mouse anti-b-actin antibody (Sigma, St. Louis, MO). Peptides (11R-VIVIT, RRRRRRRRRRR-GGG-MAGPVIVITGPH EE; 11R-VEET, RRRRRRRRRRR-GGG-MAGPPHIVEE TGPHVI) and fluorescein isothiocyanate (FITC)-conjugated peptides synthesized by Hokkaido System Science Co., Ltd (Hokkaido, Japan). The synthesized peptides were purified by reverse-phase high-performance liquid chromatography (HPLC). The purity of the products ascertained by time-of-flight mass spectrometry was more than 95%. FK506 was provided by Astellas Pharma Inc. (Tokyo, Japan) and dissolved in dimethyl sulfoxide (DMSO). All other chemicals and biochemicals were from Sigma.
Cell lines and cultures
Human articular chondrocytes (Cryo NHAC-kn) were purchased from Sanko Junyaku (Tokyo, Japan) and cultures were maintained according to the manufacturer's protocol. Chondrocytes between passages 3 and 10 were used for the analysis. OUMS-27 chondrosarcoma cells were a kind gift from Dr. T. Kunisada (Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan) [17, 18] . The cells were viewed using an Olympus IX71 microscope (Olympus Corp, Tokyo, Japan) and images were digitally captured using an Olympus DP70 (Olympus Corp). The chondrocytic phenotype of these cells was confirmed by the expression of type II collagen (COL2A1) as previously reported [19] .
Protein extraction
The cells were incubated with or without cytokines in the medium as previously reported [13] . After incubation with IL-1b (10 ng/ml) for the appropriate period, the cells were washed once with phosphate buffered saline (PBS) and then solubilized in 200 ll of cell CelLytic TM -MT Mammalian Tissue Lysis/Extraction Reagent (Sigma) containing 1 mM Na 3 VO 4 , 1 mM PMSF, 1 mM NaF, and complete protease inhibitor cocktail (Sigma). After incubation in a rotator at 4°C for 15 min, the samples were centrifuged and the supernatants were collected. The protein concentration of the cell extracts was determined by the Bio-Rad Protein Assay kit (Bio-Rad, Hercules, CA) using bovine serum albumin (BSA) as a standard.
Western blot analysis
Cell lysates (15 lg of total protein/lane) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using a 4-12% gradient gel (Ready Gel J: Bio-Rad) and then transferred onto polyvinylidene difluoride (PVDF) membranes (Bio-Rad). Membranes were blocked with 5% BSA in PBS containing 0.05% Tween 20 (PBS-T) and then incubated with primary antibody diluted in blocking buffer. The membranes were washed with PBS-T and then incubated with the horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG antibody (1:2,000; MP Biomedicals, Aurora, OH) diluted in blocking buffer.
Following three successive washes with PBS-T, immunoreactive bands were visualized using the enhanced chemiluminescence system (ECL plus; GE Healthcare, Piscataway, NJ). Signals were detected with LAS1000 (Fuji Film, Tokyo, Japan).
RNA preparation and quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) After 6 h of stimulation with recombinant human IL-1b, the cells were washed once with PBS and total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Two micrograms of total RNA was reverse-transcribed by random hexamer priming using ReverTra Ace (Toyobo, Osaka, Japan).
A quantitative real-time RT-PCR analysis was performed using a LightCycler rapid thermal cycler system (Roche Diagnostics Ltd, Mannheim, Germany) following the protocol previously reported [20, 21] . The PCR mixture consisted of 19 SYBR Green PCR Master Mix (Toyobo) which includes DNA polymerase, SYBR Green I Dye, dNTPs including dUTP, PCR buffer, 10 pmol forward and reverse primers, and cDNA of samples in a total volume of 20 ll. The amplification of a housekeeping gene, b-actin, was used for normalizing the efficiency of cDNA synthesis and the amount of RNA applied. To validate the specificity of amplification of ADAMTS9 and b-actin, we analyzed each PCR product by agarose gel electrophoresis after realtime detection. All the experiments were performed at least twice in triplicate wells. Negative controls were performed with samples in which the RNA templates were replaced by nuclease-free water in the reactions. The intra-and interassay coefficients of variations were \5% and were reasonably small in comparison to those described in other reports. Subsequently, the threshold cycle (Ct), i.e., the number of cycles at which the amount of the amplified gene of interest reached a fixed threshold, was determined. The cDNAs were subjected to real-time PCR amplification using specific primer set for ADAMTS9 and b-actin as previously described [13] . PCR reactions for NFATc1, c2, c3, and c4 were performed as described previously [22] using human thymus cDNA (MTC Panel II, K1421-1; Clontech) as a positive control. PCR was performed with initial denaturation at 94°C for 5 min, followed by amplification for 35 cycles, each cycle consisting of denaturation at 94°C for 30 s, annealing at 58°C for 30 s, and polymerization at 72°C for 40 s. Primers used for each NFAT amplification were listed in Table 1 .
Chromatin immunoprecipitation assay
For the chromatin immunoprecipitation of ADAMTS9 promoter region, a commercially available system was used (ChIP Assay Kit; Upstate/Millipore, Schwalbach, Germany) according to the manufacturer's instructions. In short, 1.5 9 10 6 cells in a 10 cm dish treated with or without IL-1b at 30 min. Chromatin was crosslinked in cell Table 1 Primers used for PCR analysis 1. For ChIP assay application (see Fig. 5a ) S1
(sense; -627) cultures by addition of formaldehyde (final concentration 1%). After that cells were washed and pelleted by centrifugation and lysed in SDS lysis buffer in the presence of protease inhibitors and incubated on ice. The cell lysates were sonicated to shear DNA to a length of 200-800 bp. The lysates were centrifuged at 13,800g at 4°C and supernatant transferred to new tubes. The supernatants were precleared with a mixture of salmon sperm DNA/ protein A agarose-50% slurry for 30 min at 4°C. Agarose was then pelleted and the supernatants were transferred to new tubes. For immunoprecipitation, an anti-NFATc1 mouse monoclonal antibody (7A6: Santa Cruz Biotechnology) was added and incubated overnight [23] . Isotype-matched mouse IgG2b (Ancel Corporation, Bayport, MN) served as a negative control. Salmon sperm DNA/protein A agarose slurry was added and incubated for 1 h at 4°C. Agarose was carefully pelleted and washed three times. Eluted chromatin was dissolved in TE buffer and agarose beads were spun down. Cross-links were reversed by addition of 20 ll 5 M NaCl to a volume of 500 ll chromatin-containing buffer and by heating of the mixture to 65°C for 4 h. EDTA and Tris-HCl buffers were added together with proteinase K. Sheared DNA was recovered by using DNA recovery kit (Nucleospin: Macherey-Nagel, Duren, Germany). For the identification of the immunoprecipitated ADAMTS9 promoter region, PCR was performed using specific primer sets (Table 1 ; Fig. 5a ). PCR was performed at 96°C for 5 min, then 96°C for 30 s, 56°C for 30 s, and 72°C for 40 s, for 30 cycles. Input DNA (genomic DNA after sonication) was used as a positive control and immunoprecipitated DNA with mouse IgG2b as a negative control for the experiments.
Construction of secreted metridia luciferase reporter plasmid
The transcription start site of the ADAMTS9 was determined by GenBank # AK310571. A schematic representation of ADAMTS9 promoter-luciferase construct is shown in Fig. 6a . A secreted luciferase assay system for the promoter analysis according to the plan designed by Hatipoglu et al. (unpublished data; named as Hirohata method). In brief, conditioned medium was sequentially collected in identical cell cultures and luciferase activity was compared before and after cytokine stimulation, respectively. Secreted Metridia longa luciferase reporter constructs (-2,845 to ?229 bp; -688 to ?229 bp; -348 to ?229 bp relative to the transcription start site) were generated using promoterless pMetLuc-Reporter vector (Clontech, Mountain View, CA). Cryo NHAC-kn genomic DNA was used to generate the pMetLuc constructs. Briefly, 5 0 primer and XhoI-site linked 3 0 primer specific for the ADAMTS9 were used for amplification by LA-Taq DNA polymerase (Table 1 ; Takara, Kyoto, Japan). Initially, amplified fragments were cloned into pCR II vector using TA Cloning Kits (Invitrogen). Inserted pCR II vector and the pMetLuc-Reporter vectors were digested with EcoRI/ XhoI and EcoRI/SalI, respectively. The inserts were ligated into a digested vector with T4 ligase (Toyobo). Finally, the nucleotide sequences of the constructs were determined by automated DNA sequencing (ABI PRISM330xl, Applied Biosystems, Foster, CA) using the BigDye Terminator Cycle Sequencing Kit (Applied Biosystems).
Transfection and secreted metridia luciferase assays Transfection was performed by the Fugene6 transfection reagent (Roche Diagnostics Ltd). Briefly, the cells were plated at a density of 1 9 10 5 cells in 12-well dishes with 1 ml of culture medium. After incubation to 50-80% confluence at 37°C under 5% CO 2 and 20% O 2 in a humidified chamber, the cells were treated with 20 TRU/ml Steptomyces hyaluronidase (Seikagaku kogyo, Tokyo, Japan) 12 h before transfection and during transfection [24] . Thereafter, the cells were transfected with 1 lg pMetLuc plasmid DNA using Fugene6 transfection reagent. Promoterless pMetLuc-reporter vector was transfected as a negative control. After 24 h of transfection the medium was collected and then incubated for another 24 h with IL-1b stimulation and the medium was collected again. The secreted luciferase was measured with the Ready-to-Glow TM secreted luciferase reporter system (Clontech) according to the manufacturer's instructions at 405 nm in a luminometer (Dainippon Sumitomo Pharma, Osaka, Japan).
Statistical analysis
Data are given as the mean value ± SD. A statistical analysis was performed using Student's t-test (*P \ 0.05, **P \ 0.01).
Results and discussion
Cloning of the 3 kb ADAMTS9 promoter A 3 kb fragment of the 5 0 -flanking region of the human ADAMTS9 gene was cloned (-2,845 to ?229). A sequence analysis of the 3 kb promoter revealed the absence of the canonical TATA box around -30 bp from the transcriptional start site. The presence of CpG islands near the transcriptional start site was indicated by the UCSC genome browser (http://genome.ucsc.edu/). These structural features are characteristic for the promoter of housekeeping genes. While the promoters of ADAMTS4 and ADAMTS5 contained TATA box-like sequence adjacent to the transcriptional start site [15, 25] . The relative location and sequence of the putative NBEs containing 'GGAAAA' are shown in Fig. 1 . In the ADAMTS9 promoter, four NBEs (NBE 1-4) are clustered in the proximal region and one NBE (NBE 5) is located in the distal promoter region (Fig. 1a) . The comparison of NBE among ADAMTS4, 5, and 9 were shown in Fig. 1b . It was demonstrated that NFAT can transactivate the ADAMTS4 promoter in SW1353 human chondrosarcoma cells [15] . As shown in Fig. 1b , The ADAMTS5 promoter contained two putative NBEs, although these were not functionally analyzed. The NBE located in the Adamts9 promoter was also observed in rat (Fig. 1c) , although mouse Adamts9 promoter did not contain NBE.
Induction of ADAMTS9 mRNA in IL-1b stimulated chondrosarcoma cells and chondrocytes
We then examined the induction of ADAMTS9 mRNA in chondrosarcoma cells (OUMS-27) and chondrocytes stimulated by IL-1b. ADAMTS9 mRNA was strongly induced as early as 6 h in OUMS-27 (eightfold increase) and then decreased (Fig. 2a) . The induction of ADAMTS9 mRNA by IL-1b was also observed in chondrocytes at 6 h (13-fold increase) but the induction was decreased at 12 h (Fig. 2b) .
Activation of the NFATc1 in IL-1b induced human chondrocytes
Since there is no available information about NFAT expression in chondrocyte, we examined RT-PCR using gene specific primers designed by Day et al. [22] . NFATc1 showed a strongest expression among NFAT members (Fig. 3a) . Then we focused on NFATc1 expression in chondrocytes. We then examined whether NFATc1 mRNA expression was induced by IL-1b in the chondrocytes. Human chondrocytes were treated for 0-24 h with IL-1 b (10 ng/ml) and the expression of NFATc1 was monitored by Western blotting (Fig. 3b) . Three variants of the NFATc1, with apparent molecular masses between 90 and 140 kDa, were detected by mouse anti-NFATc1 antibody (7A6) in the unstimulated control. There was a peak expression of NFATc1 at 3 h after the treatment and its expression was gradually decreased thereafter (Fig. 3b) . This result was closely related to the peak expression of ADAMTS9 mRNA at 6 h after IL-1b stimulation [13] . Calcineurin activates NFAT by dephosphorylating serine residues in the SP-repeats and in the [14] . Hence, the dephosphorylation of NFATc1 results in increased mobility on SDS-PAGE [26] . Treatment of human chondrocytes with ionomycine, an ionophore to raise the intracellular level of calcium (Ca 2? ), revealed the activated status of NFATc1 as a positive control (Fig. 3b) . The activated NFATc1 detected by Western blotting revealed the emergence of the bottom variant of NFATc1 at molecular mass of 75 kDa. The activated NFATc1 was detected between 3 and 12 h after treatment with IL-1b. Collectively, these results demonstrated the activated NFATc1 expression at 3 h after the treatment of chondrocytes with IL-1b.
The inhibition of the ADAMTS9 expression induced by IL-1b in human chondrocytes and OUMS-27 chondrosarcoma cell lines ADAMTS9 is the most highly induced of the aggrecanase family genes in IL-1b-stimulated chondrosarcoma-derived cells (OUMS-27) and isolated articular chondrocytes [13] . To test the possibility regarding whether NFAT mediates the induction of ADAMTS9, two inhibitors for NFAT were used, FK506 and 11R-VIVIT. FK506, an immunosuppressive drug, disrupts calcineurin phosphatase activity by forming FK506-FKBP12 complexes. While undoubtedly effective, a major setback of this calcineurin inhibitor is B C Fig. 1 continued that it intervenes in calcineurin activity, affecting all of the downstream signal transduction pathways of calcineurin and leading to undesired side-effects and toxicity in nonimmune cells [27, 28] . In contrast, the 11R-VIVIT peptide selectively inhibits NFAT activation via the prevention of the protein-protein interactions of calcineurin and NFAT. The specific interruption of calcineurin docking onto NFAT will allow efficient NFAT inactivation without affecting other calcineurin targets such as NF-jB, myocyte enhancer factor-2 (MEF2), and the apoptotic factor Bad [29] . A novel NFAT inhibitor peptide, VIVIT, was first developed by Aramburu et al. [11] . In addition, a negative control peptide, VEET, was constructed by scrambling the sequence of VIVIT amino acids [12] . For efficient transduction, 11-arginine (11R) was linked to the C-terminal of the VIVIT and VEET peptides [30] . To examine whether FITC-conjugated 11R-VIVIT and 11R-VEET transduce human chondrocytes were treated with FITC-conjugated 11R-VIVIT and 11R-VEET peptides. Two hours after transduction, FITC-conjugated peptides were observed as a fluorescent signal in all living chondrocytes. The quantity of uptake peptides was similar for both peptides and the peptides were distributed throughout the cells as seen in Fig. 4a, b . Human chondrocytes and OUMS-27 cells were treated with 11R-VIVIT, 11R-VEET, or FK506 for 2 h, then with IL-1b for an additional 6 h. After 6 h incubation, the total mRNA was isolated, transcribed to cDNA and real-time PCR analysis was performed for ADAMTS9 expression. In the presence of the IL-1b, ADAMTS9 expression increased nearly 13-fold higher in human chondrocytes (Fig. 4c ) and 10-fold higher in OUMS-27 cells (Fig. 4d) relative to the untreated conditions. ADAMTS9 expression was decreased to nearly 40-50% by 1 lM of 11R-VIVIT (Fig. 4c) , but higher concentrations showed no further inhibition (data not shown). Scrambled peptide (11R-VEET) did not change ADAMTS9 expression level. One lM of FK506 inhibited a little bit more (55%) than 11R-VIVIT peptides (Fig. 4d) . These results indicate Chondrocytes could easily differentiate and become fibroblast-like cells. Differentiated cells lose their ability to produce cartilage specific markers such as collagen type II. Therefore, the cellular phenotype was checked by both observing the cell shapes and performing PCR using specific primer sets for collagen type II as described previously [19] (data not shown).
NFATc1 binds to ADAMTS9 promoter under IL-1b stimulation in human chondrocytes
A ChIP assay is a beneficial technique to evaluate the association of proteins with specific DNA regions. A ChIP assay was performed to determine whether NFATc1 binds directly to the putative NBEs (NBE [1] [2] [3] [4] [5] found in the ADAMTS9 promoter. DNA-protein complexes were immunoprecipitated with anti-NFATc1 antibody, the crosslinks were reversed and the recovered DNA fragments were monitored by PCR using primers for distal NBE (NBE 5) and for proximal NBEs (NBE 1-4), respectively (Fig. 5a) . DNA fragments immunoprecipitated with monoclonal antibody against NFATc1 (7A6) [23] could be amplified by PCR using the indicated primers for both the NBE regions under IL-1b stimulation (Fig. 5b, c) , whereas those immunoprecipitated with normal goat IgG could not. These results indicate that NFATc1 binds directly to the both the distal and proximal NBEs in the ADAMTS9 promoter.
Deletion analysis of the human ADAMTS9 promoter Initially, the transcriptional activity of the pMetLuc -2,845/?229 plasmid, containing the 2.8 kb upstream sequence of human ADAMTS9 gene, was examined in Cryo NHAC-kn, a human primary articular chondrocytes and in OUMS-27, a human chondrosarcoma cell line. Transfection of pMetLuc -2,845/?229 plasmid yielded a high level of luciferase enzyme activity in both cells (Table 2 ). This result suggests that the 2.8 kb promoter sequence contains basic regulatory elements. To further assess the functional involvement of distal and proximal NBEs for ADAMTS9 induction by IL-1b, 5 0 stepwise deletion constructs were generated as shown in Fig. 6a . pMetLuc -2,845/?229 contains both distal and proximal NBEs, while pMetLuc -688/?229 contains only proximal NBEs (NBE 1-4) . The shortest construct (pMetLuc -348/?229) lacks all of these NBEs. pMetLuc -2,845/?229 exhibited the highest induction by IL-1b (fourfold) and a decrease in pMetLuc -688/?229 was observed, however, it still maintained a moderate level of induction (2.5-fold). The shortest construct (pMetLuc -348/?229) did not show any obvious induction (Fig. 6b) . These results are consistent with the results of the ChIP assay, which indicated the direct binding of NFAT in both of distal and proximal NBEs.
The current study, demonstrated the VIVIT peptide to be one of the novel inhibitory agents for ADAMTS9 induced by IL-1b via NFAT signaling. To find a good inhibitory agent for aggrecanases, ADAMTS9 was selected as a target gene to investigate due to the highest activation by IL-1b among aggrecanases [13] . The promoter region analysis of the aggrecanases (ADAMTS4, ADAMTS5, and ADAMTS9) revealed the presence of NBEs as a potential regulatory elements of aggrecanase (Fig. 1) . This was the first observation of NFAT up-regulation and activation by IL-1b in the human chondrocytes (Fig. 3) . The efficient uptake of 11R-VIVIT peptide by human chondrocytes was demonstrated for the first time in this study (Fig. 4) . The 11R-VIVIT could inhibit nearly half of the ADAMTS9 expression induced by IL-1b (Fig. 4) . In support of this idea, it should be determined whether 11R-VIVIT can suppress the expression of ADAMTS4 and ADAMTS5 under inflammatory conditions. These observations are expected to shed some light on the potential use of 11R-VIVIT for the treatment of cartilage degeneration seen in OA or RA.
Subsequent studies could further indicate that both of distal and proximal NBEs are functionally involved in the induction of ADAMTS9 by IL-1b. However, it was not possible to identify which one of the proximal NBEs (NBE 1-4) is functional and most important for such induction. To determine this, a series of substitution mutations in the luciferase construct would thus be required. As a potential transcription factor of aggrecanases, Runx2 is suggested to be involved in the regulation of ADAMTS4 and ADAMTS5 in chondrocytic cells [15, 25] . The combination of different transcription factors in regulating gene expression has been widely observed. Therefore, the identification of transcription factors and signaling pathways induced by inflammatory cytokines deserves further study to fully understand the mechanism underlying cartilage matrix degradation. deletion of ADAMTS9 promoter. 5 0 deletion fragments of ADAMTS9 promoter were generated by PCR and were ligated in the upstream of the Secreted Metridia longa luciferase gene in the pMetLuc-Reporter vector. The location of the NBEs is shown. b Relative Luciferase Activity. OUMS-27 and chondrocytes were transfected with three promoter deletion constructs. After 24 h, the medium was collected, and then replaced to the fresh medium containing IL-1b. Secreted Luciferase activity in medium was measured 24 h post-cytokine treatment. The relative secreted luciferase activity in the medium was calculated by the ratio of cytokines treatment medium to nontreatment medium. Luciferase activity were normalized to the activity of control (value = 1) and represent mean ± SD. Significance compared to the control *P \ 0.05
